MM cells are BCMA− in a minority of cases [53], and BCMA downregulation or loss has been observed in relapsed patients after BCMA-directed CAR-T therapy [10, 12, 29, 36], highlighting the rationale for targeting an additional antigen. Here, TNFRSF17 is linked to Miyoshi myopathy.